Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10312MR)

This product GTTS-WQ10312MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10312MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5586MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP7766
GTTS-WQ9043MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ14108MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aNGF75
GTTS-WQ10223MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ10144MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LBR-101
GTTS-WQ3131MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ10378MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ3304MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ASN-100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW